Brii Biosciences (2137 HK)

Analysis

Health Care • China

Brii Biosciences is a biotechnology company focused on developing therapies for infectious and central nervous system diseases. The company has a broad pipeline of therapeutic candidates, with lead programs targeting hepatitis B virus (HBV) infection, and also develops treatments for multi-drug resistant bacterial infections. Brii Biosciences is headquartered in Beijing, China, and was founded in 2017.

Refresh

Exchange Announcement • 14 Oct 2026 21:46

Next Day Disclosure Return

Exchange Announcement • 13 Oct 2026 22:14

Next Day Disclosure Return

Exchange Announcement • 12 Oct 2026 21:34

Next Day Disclosure Return

Exchange Announcement • 09 Oct 2026 21:59

Next Day Disclosure Return

Exchange Announcement • 08 Oct 2026 22:02

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Grant Of Share Options And Restricted Share Units